19-334 - Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
Status: openA PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
Treatment for Melanoma
Description
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Sponsors
This trial is sponsored by SWOG.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Principle Investigator
Providers Associated With This Trial
![Sachin Pai]()
View ProfileSachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology![Moh'd Khushman]()
View ProfileMoh'd Khushman, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology![Poosarla_T2]()
View ProfileTeja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
